Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned

Prime Medicine, Inc.

Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.
On track to file IND/CTA for Wilson Disease (1H 2026) and AATD (mid-2026); initial clinical data expected 2027.
Engaging FDA for PM359 in CGD; plans BLA based on Phase 1/2 data published in NEJM, targeting accelerated approval.
Workforce reduction and deprioritization of CGD program to focus on in vivo liver franchise.
CF program preclinical proof-of-concept data expected 2026; BMS CAR-T collaboration continues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.